All News

Cema-cel received RMAT and fast track designations for first-line consolidation therapy in MRD-positive large B-cell lymphoma based on phase 2 ALPHA3 data.

María Teresa Bourlon, MD, MSc, FASCO, discussed why early RadiCal trial closure and adverse effects outweigh secondary survival signals in bone-metastatic RCC.

Explore modern metastatic breast cancer care: longer survival, smarter symptom control, caregiver support, and steps to close racial treatment gaps.

María Teresa Bourlon, MD, MSc, FASCO, discussed data showing body composition and muscle loss with lenvatinib/everolimus vs cabozantinib in metastatic ccRCC.

In part 1 of a 2-part interview, Frank McCormick, PhD, discusses the technical hurdles that made KRAS resistant to drug development, the NCI's RAS Initiative, and the RASolute 302 data.

Data from a first-in-human phase 1 trial assessing ISM6331 in mesothelioma and other solid tumors will be presented at the ESMO Congress 2026.

Key genitourinary oncology updates emerged from ASCO 2026, focusing on balancing efficacy and AEs.

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, says equitable access to CAR T-cell therapy depends on partnership, not just center certification.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed overcoming insurance barriers to oral AML treatment access.

Final phase 3 BOND-003 Cohort C results showed a 75.5% complete response rate with cretostimogene grenadenorepvec in BCG-unresponsive NMIBC.

Risvutatug rezetecan improved progression-free survival in the phase 3 ARTEMIS-011 trial for patients with relapsed osteosarcoma.

No adverse effects or injuries associated with the presence of particulate matter in 3 lots of injectable cyclophosphamide have been reported to date.

Clinicians “still don’t have the answer” on true toxicity thresholds, says Tiba Al Sagheer, PharmD, BCOP, BCACP, on CAR T-cell toxicity management.

As the FDA's ODAC prepares to weigh in ahead of an August 2, 2026, decision date, take a look at RP1's clinical trial and regulatory journey.

Approval of the SimpleScreen CRC test may increase earlier detection of colorectal cancer and improve patient outcomes.

Experts discuss how to properly select first-line regimens for EGFR-mutated NSCLC in the context of different clinical scenarios.

Sonesitatug vedotin met dual primary survival end points in the phase 3 CLARITY-Gastric01 trial in CLDN18.2-positive gastric/GEJ cancer.

Health-related quality of life was comparable between belzutifan plus lenvatinib and cabozantinib among those with previously treated renal cell carcinoma.

In a phase 3 trial, ensartinib raised the 24-month disease-free survival rate to 86.4% vs 53.5% with placebo in patients with resected ALK-positive NSCLC.

Courtney D. DiNardo, MD, MSCE, and Michael R. Savona, MD, shared antiemetic strategies for GI AEs with oral AML regimens.

Presenters at the 2026 National ICE-T Conference in Orlando, Florida, discuss the efficacy and safety of novel agents across hematologic disease states.

Tiba Al Sagheer, PharmD, BCOP, BCACP, said CAR T-cell expansion signals toxicity risk differently across cilta-cel and ide-cel.

Michael R. Savona, MD, and Courtney D. DiNardo, MD, MSCE, discussed ARC initiative data on venetoclax dose modifications in AML.

"I can’t make [treatment] decisions for you, but I can give you realistic expectations," said Herbert Lepor, MD, of NYU Langone Health.

A multidisciplinary panel discussed second-line CAR T-cell candidacy, real-world referral barriers, and the management of delayed toxicities in DLBCL.

Kathryn Eckert, DO, spoke about diversifying breast imaging technology after the Hologic Brevera needle recall.

Herbert Lepor, MD, outlines NYU Langone’s long-term PSA and MRI surveillance protocol following focal cryoablation for prostate cancer.

Paul Oberstein, MD, discusses how RASolute 302 may be the most significant advance in pancreatic cancer treatment in more than a decade.

Differentiating between CRS and IEC-HS remains a challenge in mitigating toxicity associated with cellular therapy, said Tiba Al Sagheer, PharmD, BCOP, BCACP.

Among evaluable patients with B-cell NHL from the dose-escalation portion of the trial without CNS involvement, all CRs were sustained through 6 months.